Cell division cycle 20 homologue (CDC20) is a well-known regulator of cell cycle, as it
controls the correct segregation of chromosomes during mitosis. Many studies have focused …

Simple Summary Multiple myeloma (MM), a malignant plasma cell disorder, is characterized
by abnormal DNA damage response (DDR). MM cells adapt over time via gene mutations or …

Multiple myeloma (MM) patients with t (11; 14) present unique biological features and their
prognosis is not well established. We report a retrospective study of 591 MM patients, 17.3 …

The median overall survival in multiple myeloma is rapidly approaching 10 years; however,
in nearly a fifth of patients the prognosis remains poor. Therefore, the modern‐day …

PBX1 is a critical transcription factor at the top of various cell fate-determining pathways. In
cancer, PBX1 stands at the crossroads of multiple oncogenic signaling pathways and …

Raltegravir, the first integrase inhibitor approved for the treatment of HIV infection, has been
implicated as a promising potential in cancer treatment. Therefore, the present study aimed …

Multiple myeloma (MM) is a heterogeneous and complex disease, both in mutational biology
as well as in the clinical presentation of patients. While tailored and biomarker‐targeted …

Multiple myeloma (MM) remains an incurable hematological malignancy demanding
innovative therapeutic strategies. Targeting MYC, the notorious yet traditionally undruggable …

Multiple myeloma cells aberrantly express surface antigens compared with normal plasma
cells. Among others, CD56 is present at variable levels in approximately 70% of patients …

Multiple myeloma (MM) is a genetically complex and heterogeneous neoplasm in which
cytogenetics is a major factor playing an important role in the risk stratification of disease …